Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances

• US 20080214987A1
• Filed: 12/20/2007
• Published: 09/04/2008
• Est. Priority Date: 12/22/2006
• Status: Abandoned Application

• Current Assignee: Nanomed Devices Incorporated
• Original Assignee: Nanomed Devices Incorporated
• Inventors: Xu, Bai
• Application Number:
  US11/961,816
• Publication Number:
  US 20080214987A1
• Time in Patent Office: Days
• US Class Current: 604/21
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/003 having a lumen
• CPC Class Codes: A61M 2037/0046 Solid microneedles
• CPC Class Codes: A61M 2037/0061 Methods for using microneedles
• CPC Class Codes: A61M 37/0015 by using microneedles
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A system and method of using a high-aspect ratio microdevice for treating, preventing or ameliorating a medical condition is provided.

Claims

1. A method of delivering an agent or a combination of agents, for a medical condition to a mammal, comprising

applying an applicator to a microdevice to cause the microdevice to contact an area of skin of the mammal to generate a prepared area of skin comprising a plurality of nanopores or nanochannels through the stratum corneum of the area of skin,

applying a wet formulation comprising the agent the prepared area of skin, and

causing an effective amount of agent to deliver to the patient through the nanopores or nanochannels in the stratum corneum;

wherein the applicator comprises a spring powered mechanical applicator, an ultrasound applicator, or a battery powered mechanical vibrator.

2. The method of claim 1, wherein causing an effective amount of the agent to deliver to the patient comprises:

allowing the agent to diffuse into the patient from the formulation, or

driving the agent into the patient by applying a driving force to the formulation.

3. The method of claim 1, wherein agent is encapsulated within elastic liposomes.

4. The method of claim 1, wherein the wet formulation does not comprise elastic liposomes.

5. The method of claim 1, wherein the elastic liposome comprises liposome nanoparticles.

6. The method of claim 2, wherein the driving force is selected from iontophoresis, sonophoresis, radiofrequency (RF), heat gradient or a combination of these.

7. The method of claim 1, wherein the mammal has a medical condition,

wherein the agent is a natural or synthetic vaccine selected from the group consisting of proteins, peptides, paclitaxel, docetaxel, vaccines, protein vaccines, peptide vaccines, gene vaccines and DNA vaccines, and

wherein the vaccine is against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera.

8. The method of claim 1, wherein the agent is a pain relieving agent.

9. The method of claim 8, wherein the medical condition is chronic back pain.

10. The method of claim 8, wherein the medical condition is a cancer.

11. The method of claim 8, wherein the medical condition is pre-surgery pain management, operation room pain management or post-surgery pain management.

12. The method of claim 8, wherein the pain relieving agent is lidocaine, or tetracaine or dyclonine or a combination of thereof, and

wherein the formulation is a topical or systemic delivery formulation selected from lotion, cream, gel patch, ointment or skin patch comprising lidocaine or tetracaine or dyclonine or a combination of thereof.

13. The method of claim 1, wherein the formulation is a topical or systemic delivery formulation selected from a skin patch, cream, ointment, or lotion.

14. The method of claim 13, wherein the mammal is a human being, and wherein the medical condition is cancer pain, post-surgery pain and lower back pain.

15. The method of claim 1, wherein the formulation is a wet skin patch.

16. A kit for delivering an agent to a mammal, comprising

a microdevice comprising a structure selected from microneedles, microblades, microknives, and combinations thereof;

a wet formulation comprising a bioactive agent; and

a mechanism to provide for a driving force.

17. The kit of claim 16, wherein the driving force is ultrasound, iontophoresis, radio frequency or heat gradient.

18. The kit of claim 16, further comprising

an applicator of the microdevice for applying the microdevice to an area of skin of a mammal.

19. The kit of claim 16, further comprising

a driving force mechanism for driving the bioactive agent to transport through the stratum corneum of the area of skin into the mammal.

20. The kit of claim 16, wherein the mammal has a medical condition,

wherein the agent is a natural or synthetic vaccine selected from the group consisting of proteins, peptides, paclitaxel, docetaxel, vaccines, protein vaccines, peptide vaccines, gene vaccines and DNA vaccines, and

wherein the vaccine is against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera.

21. The kit of claim 16, wherein the formulation comprises elastic liposomes encapsulating the agent.

22. The kit of claim 16, wherein the formulation does not comprises elastic liposomes.

23. The kit of claim 21, wherein the elastic liposome comprises deformable nanoparticles.

24. The kit of claim 16, wherein the formulation is a topical or systemic delivery formulation selected from a skin patch, cream, ointment, or lotion.

25. The kit of claim 16, wherein the driving force mechanism comprises ultrasound, or radio frequency, heat gradient or iontophoresis device.

26. The kit of claim 16, wherein the agent is a pain relieving agent.

27. The kit of claim 24, wherein the medical condition is chronic back pain.

28. The kit of claim 24, wherein the medical condition is a cancer.

29. The kit of claim 24, wherein the medical condition is pre-surgery pain management, operation room pain management or post-surgery pain management.

30. The kit of claim 26, wherein the pain relieving agent is lidocaine, or tetracaine or dyclonine or a combination of thereof, and

wherein the formulation is lotion, cream, gel patch, ointment or skin patch comprising lidocaine or tetracaine or dyclonine or a combination of thereof.

31. The kit of claim 16, wherein the formulation is a topical or systemic delivery formulation selected from a skin patch, cream, ointment, or lotion.

32. The kit of claim 30, wherein the mammal is a human being having a medical condition selected from cancer pain, post-surgery pain and lower back pain.

33. The kit of claim 16, wherein the applicator is a mechanical applicator.

34. The kit of claim 16, wherein the formulation is a wet skin patch.

35. An applicator for mechanical skin treatment comprising:

(a) a housing having a plurality of walls defining an interior space, the interior space having an upper opening permitting selective access to the interior space of the housing, a cover member being removably couplable to the housing such that the cover is for closing the upper opening of the interior space of the housing; and

(b) a plurality of microneedle head portion connected to a base portion being removably insertable into the interior space of the housing, each of the applicators being adapted for aiding a user to treat skin;

wherein the plurality of the applicator including a microneedle array assembly comprising

(i) the microneedle array assembly being adapted for selectively treating skin, and

(ii) the microneedle assembly having a head portion and a base portion, the head portion being selectively couplable to the base portion such that the base portion is insertable into the interior space of the housing, the base portion of the microneedle array assembly having a pair of depressions, each of the depressions extending along a portion of a length of the base portion, one of the depressions being positioned opposite the other of the depressions such that the depressions are adapted for receiving finger tips of a hand of the user for inhibiting slipping of the base portion from the hand of the user of the applicator.

36. The applicator of claim 35, wherein the base portion of the microneedle applicator further comprises a motor assembly being positioned in the base portion, the head portion having a drive assembly being positioned in the head portion, the drive assembly being operationally coupled to a base portion, the base portion outwardly extending from an upper end of the head portion, the motor assembly being operationally coupled to the drive assembly such that the motor assembly is for actuating the drive assembly, the drive assembly being for oscillating the base portion when the drive assembly is actuated by the motor assembly.

37. The applicator of claim 36, wherein the head portion comprises a plurality of microneedles extending from the base portion, the microneedles being adapted for treat the skin when the microneedle head portion is oscillated by the drive assembly.

38. The applicator of claim 36, wherein the motor assembly comprises a motor, the motor having a shaft extending from the motor, the motor being for actuating the shaft, the shaft being for operationally coupling to the drive assembly of the base and head portions such that actuation of the shaft actuates the drive assembly, a power source being operationally coupled to the motor such that the power supply is for providing power to the motor.

39. The applicator of claim 35, comprising a heavy eccentric mass designed to produce vibration upon actuation of the motor, wherein the motor is actuated to bring the base and head portions into vibration so that skin treatment is practiced through the aid of the vibration, the microneedle application method comprising the steps of:

predetermining respective weights of the electric applicator and the heavy eccentric mass as well as an eccentric location of the center of gravity of the heavy eccentric mass;

establishing an output of the motor at about 1000-15000 rpm in accordance with the predetermined conditions;

producing a vibration of about 1000-15000 rpm by actuating the motor;

conducting the vibration to tips of microneedle on the head portion to increase a pressing force acting along an axial direction of the base and head portion by the use of a minute circular ring connecting to the handle part and pressing against skin area need treatment.

40. The applicator of claim 35, wherein the motor assembly comprises a switch, the switch being operationally coupled between the power supply and the motor, the switch being for controlling power from the power supply to the motor.